Inventiva S.A. (EPA:IVA)
3.600
+0.190 (5.57%)
Oct 31, 2025, 5:35 PM CET
Inventiva Revenue
Inventiva had revenue of 5.61M EUR in the half year ending June 30, 2025, a decrease of -15.28%. This brings the company's revenue in the last twelve months to 16.97M, down -10.36% year-over-year. In the year 2024, Inventiva had annual revenue of 14.09M, down -38.24%.
Revenue (ttm)
16.97M
Revenue Growth
-10.36%
P/S Ratio
29.52
Revenue / Employee
202.02K
Employees
118
Market Cap
500.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
Inventiva News
- 19 days ago - Inventiva Announces the Implementation of a New ATM Program - GlobeNewsWire
- 24 days ago - Inventiva (IVA) Gets Boosted Price Target from HC Wainwright & Co. | IVA Stock News - GuruFocus
- 24 days ago - Inventiva S.A. (IVA) Analyst/Investor Day - Slideshow - Seeking Alpha
- 24 days ago - Inventiva S.A. (IVA) Analyst/Investor Day Transcript - Seeking Alpha
- 26 days ago - Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 4 weeks ago - Inventiva Names Andrew Obenshain CEO - Nasdaq
- 4 weeks ago - Inventiva Appoints Andrew Obenshain as Chief Executive Officer - GlobeNewsWire
- 4 weeks ago - Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga